Researchers from the Cure Group Four Consortium, supported by MBI and focused on high-impact investigations into pediatric brain tumors, have recently published two articles in the Nature group.
The articles feature the co-authorship of scientists from the Cure Group Four, whose research is backed by MBI and dedicated to groundbreaking studies on pediatric brain tumors.
Nature Biomedical Engineering is one of the most influential specialized journals in the Nature group. Its focus is on technological innovations applied to medicine, with direct impact in areas such as cell therapies, biomedical devices, and tissue bioengineering.
In the article published on July 18, 2025, researchers Elias J. Sayour and Duane A. Mitchell (University of Florida) present an innovative approach to making resistant tumors more sensitive to immunotherapy by amplifying the body’s immune response. This advancement may directly benefit children facing relapses or those who do not respond to traditional treatments.
Read the full article:
Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading.
Nature is considered the world’s leading scientific publication. With more than 150 years of history, it is known for publishing pioneering and transformative discoveries in biology, medicine, physics, and the natural sciences.
In the article published on May 7, 2025, scientists Lena M. Kutscher and Stefan M. Pfister (Heidelberg University) use single-cell technologies to investigate the cellular origin and evolution of medulloblastoma. The findings shed light on how tumors develop, why some resist therapy, and how we can anticipate and counteract this resistance.
These scientific achievements are also the achievements of those who believe in and support the cause: families, donors, and all partners of the Medulloblastoma Initiative. Being mentioned in two Nature group journals just two months apart is a clear sign that we are on the right path — driving discoveries that can transform the future of childhood cancer treatment.
Read the full article:
Oncogene aberrations drive medulloblastoma progression, not initiation.
Each breakthrough is a step toward a cure. And every contribution makes this journey possible.
